{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T16:32:36Z","timestamp":1791304356883,"version":"4.3.1"},"reference-count":76,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2021,6,3]],"date-time":"2021-06-03T00:00:00Z","timestamp":1622678400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,6,3]],"date-time":"2021-06-03T00:00:00Z","timestamp":1622678400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["KL2-TR001879"],"award-info":[{"award-number":["KL2-TR001879"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Cardiol Rep"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1007\/s11886-021-01516-0","type":"journal-article","created":{"date-parts":[[2021,6,3]],"date-time":"2021-06-03T05:06:35Z","timestamp":1622696795000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Therapeutic Outcomes with Surgical and Medical Management of Primary Aldosteronism"],"prefix":"10.1007","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3786-3638","authenticated-orcid":false,"given":"Heather","family":"Wachtel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas L.","family":"Fraker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,6,3]]},"reference":[{"issue":"1","key":"1516_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11906-004-0001-0","volume":"6","author":"GP Rossi","year":"2004","unstructured":"Rossi GP. Primary aldosteronism: a needle in a haystack or a yellow cab on Fifth Avenue? Curr Hypertens Rep. 2004;6(1):1\u20134.","journal-title":"Curr Hypertens Rep"},{"issue":"11","key":"1516_CR2","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1016\/j.jacc.2006.07.059","volume":"48","author":"GP Rossi","year":"2006","unstructured":"Rossi GP, Bernini G, Caliumi C, Desideri G, Fabris B, Ferri C, et al. A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. J Am Coll Cardiol. 2006;48(11):2293\u2013300. https:\/\/doi.org\/10.1016\/j.jacc.2006.07.059.","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"1516_CR3","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.cjca.2012.03.010","volume":"28","author":"D Clark 3rd","year":"2012","unstructured":"Clark D 3rd, Ahmed MI, Calhoun DA. Resistant hypertension and aldosterone: an update. Can J Cardiol. 2012;28(3):318\u201325. https:\/\/doi.org\/10.1016\/j.cjca.2012.03.010.","journal-title":"Can J Cardiol"},{"issue":"1","key":"1516_CR4","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1530\/eje-11-1013","volume":"167","author":"A Hannemann","year":"2012","unstructured":"Hannemann A, Bidlingmaier M, Friedrich N, Manolopoulou J, Spyroglou A, V\u00f6lzke H, et al. Screening for primary aldosteronism in hypertensive subjects: results from two German epidemiological studies. Eur J Endocrinol. 2012;167(1):7\u201315. https:\/\/doi.org\/10.1530\/eje-11-1013.","journal-title":"Eur J Endocrinol"},{"issue":"7","key":"1516_CR5","doi-asserted-by":"publisher","first-page":"2826","DOI":"10.1210\/jc.2016-1472","volume":"101","author":"SC K\u00e4yser","year":"2016","unstructured":"K\u00e4yser SC, Dekkers T, Groenewoud HJ, van der Wilt GJ, Carel Bakx J, van der Wel MC, et al. Study heterogeneity and estimation of prevalence of primary aldosteronism: a systematic review and meta-regression analysis. J Clin Endocrinol Metab. 2016;101(7):2826\u201335. https:\/\/doi.org\/10.1210\/jc.2016-1472.","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"1516_CR6","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1291\/hypres.20.85","volume":"20","author":"A Tanabe","year":"1997","unstructured":"Tanabe A, Naruse M, Naruse K, Hase M, Yoshimoto T, Tanaka M, et al. Left ventricular hypertrophy is more prominent in patients with primary aldosteronism than in patients with other types of secondary hypertension. Hypertens Res. 1997;20(2):85\u201390.","journal-title":"Hypertens Res"},{"issue":"12","key":"1516_CR7","doi-asserted-by":"publisher","first-page":"2399","DOI":"10.1097\/HJH.0b013e32831286fd","volume":"26","author":"G Bernini","year":"2008","unstructured":"Bernini G, Galetta F, Franzoni F, Bardini M, Taurino C, Bernardini M, et al. Arterial stiffness, intima-media thickness and carotid artery fibrosis in patients with primary aldosteronism. J Hypertens. 2008;26(12):2399\u2013405. https:\/\/doi.org\/10.1097\/HJH.0b013e32831286fd.","journal-title":"J Hypertens"},{"issue":"9","key":"1516_CR8","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1016\/j.amjhyper.2006.02.002","volume":"19","author":"B Strauch","year":"2006","unstructured":"Strauch B, Petrak O, Wichterle D, Zelinka T, Holaj R, Widimsky J Jr. Increased arterial wall stiffness in primary aldosteronism in comparison with essential hypertension. Am J Hypertens. 2006;19(9):909\u201314. https:\/\/doi.org\/10.1016\/j.amjhyper.2006.02.002.","journal-title":"Am J Hypertens"},{"issue":"2","key":"1516_CR9","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1161\/01.HYP.0000230444.01215.6a","volume":"48","author":"GP Rossi","year":"2006","unstructured":"Rossi GP, Bernini G, Desideri G, Fabris B, Ferri C, Giacchetti G, et al. Renal damage in primary aldosteronism: results of the PAPY Study. Hypertension. 2006;48(2):232\u20138. https:\/\/doi.org\/10.1161\/01.HYP.0000230444.01215.6a.","journal-title":"Hypertension."},{"issue":"5","key":"1516_CR10","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1161\/01.HYP.27.5.1039","volume":"27","author":"GP Rossi","year":"1996","unstructured":"Rossi GP, Sacchetto A, Visentin P, Canali C, Graniero GR, Palatini P, et al. Changes in left ventricular anatomy and function in hypertension and primary aldosteronism. Hypertension. 1996;27(5):1039\u201345.","journal-title":"Hypertension."},{"issue":"2","key":"1516_CR11","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1161\/hypertensionaha.113.01060","volume":"62","author":"S Savard","year":"2013","unstructured":"Savard S, Amar L, Plouin PF, Steichen O. Cardiovascular complications associated with primary aldosteronism: a controlled cross-sectional study. Hypertension. 2013;62(2):331\u20136. https:\/\/doi.org\/10.1161\/hypertensionaha.113.01060.","journal-title":"Hypertension."},{"issue":"8","key":"1516_CR12","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1016\/j.jacc.2005.01.015","volume":"45","author":"P Milliez","year":"2005","unstructured":"Milliez P, Girerd X, Plouin PF, Blacher J, Safar ME, Mourad JJ. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol. 2005;45(8):1243\u20138. https:\/\/doi.org\/10.1016\/j.jacc.2005.01.015.","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"1516_CR13","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1161\/HYPERTENSIONAHA.108.111369","volume":"51","author":"GP Rossi","year":"2008","unstructured":"Rossi GP, Bolognesi M, Rizzoni D, Seccia TM, Piva A, Porteri E, et al. Vascular remodeling and duration of hypertension predict outcome of adrenalectomy in primary aldosteronism patients. Hypertension. 2008;51(5):1366\u201371.","journal-title":"Hypertension."},{"issue":"4","key":"1516_CR14","doi-asserted-by":"publisher","first-page":"258","DOI":"10.7326\/0003-4819-135-4-200108210-00010","volume":"135","author":"AM Sawka","year":"2001","unstructured":"Sawka AM, Young WF, Thompson GB, Grant CS, Farley DR, Leibson C, et al. Primary aldosteronism: factors associated with normalization of blood pressure after surgery. Ann Intern Med. 2001;135(4):258\u201361.","journal-title":"Ann Intern Med"},{"issue":"12","key":"1516_CR15","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1038\/ajh.2010.169","volume":"23","author":"LA Sechi","year":"2010","unstructured":"Sechi LA, Colussi G, Di Fabio A, Catena C. Cardiovascular and renal damage in primary aldosteronism: outcomes after treatment. Am J Hypertens. 2010;23(12):1253\u201360. https:\/\/doi.org\/10.1038\/ajh.2010.169.","journal-title":"Am J Hypertens"},{"issue":"3","key":"1516_CR16","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1097\/SLA.0b013e318165c075","volume":"247","author":"R Zarnegar","year":"2008","unstructured":"Zarnegar R, Young WF Jr, Lee J, Sweet MP, Kebebew E, Farley DR, et al. The aldosteronoma resolution score: predicting complete resolution of hypertension after adrenalectomy for aldosteronoma. Ann Surg. 2008;247(3):511\u20138. https:\/\/doi.org\/10.1097\/SLA.0b013e318165c075.","journal-title":"Ann Surg"},{"issue":"6","key":"1516_CR17","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1016\/j.surg.2014.08.021","volume":"156","author":"H Wachtel","year":"2014","unstructured":"Wachtel H, Cerullo I, Bartlett EK, Kelz RR, Cohen DL, Karakousis GC, et al. Long-term blood pressure control in patients undergoing adrenalectomy for primary hyperaldosteronism. Surgery. 2014;156(6):1394\u2013402; discussion402-3. https:\/\/doi.org\/10.1016\/j.surg.2014.08.021.","journal-title":"Surgery"},{"key":"1516_CR18","first-page":"215","volume":"68","author":"JW Conn","year":"1955","unstructured":"Conn JW, Louis LH. Primary aldosteronism: a new clinical entity. Trans Assoc Am Phys. 1955;68:215\u201331 discussion, 31-3.","journal-title":"Trans Assoc Am Phys"},{"issue":"3","key":"1516_CR19","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1210\/jc.2003-031337","volume":"89","author":"P Mulatero","year":"2004","unstructured":"Mulatero P, Stowasser M, Loh KC, Fardella CE, Gordon RD, Mosso L, et al. Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents. J Clin Endocrinol Metab. 2004;89(3):1045\u201350.","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"1516_CR20","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1161\/hypertensionaha.119.14063","volume":"75","author":"J Burrello","year":"2020","unstructured":"Burrello J, Monticone S, Losano I, Cavagli\u00e0 G, Buffolo F, Tetti M, et al. Prevalence of hypokalemia and primary aldosteronism in 5100 patients referred to a tertiary hypertension unit. Hypertension. 2020;75(4):1025\u201333. https:\/\/doi.org\/10.1161\/hypertensionaha.119.14063.","journal-title":"Hypertension."},{"issue":"8","key":"1516_CR21","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1097\/hjh.0000000000001384","volume":"35","author":"E Rossi","year":"2017","unstructured":"Rossi E, Perazzoli F, Negro A, Magnani A. Diagnostic rate of primary aldosteronism in Emilia-Romagna, Northern Italy, during 16 years (2000-2015). J Hypertens. 2017;35(8):1691\u20137. https:\/\/doi.org\/10.1097\/hjh.0000000000001384.","journal-title":"J Hypertens"},{"issue":"7","key":"1516_CR22","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1038\/s41371-020-0336-2","volume":"34","author":"R Libianto","year":"2020","unstructured":"Libianto R, Fuller PJ, Young MJ, Yang J. Primary aldosteronism is a public health issue: challenges and opportunities. J Hum Hypertens. 2020;34(7):478\u201386. https:\/\/doi.org\/10.1038\/s41371-020-0336-2.","journal-title":"J Hum Hypertens"},{"issue":"5","key":"1516_CR23","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1210\/jc.2015-4061","volume":"101","author":"JW Funder","year":"2016","unstructured":"\u2022\u2022 Funder JW, Carey RM, Mantero F, Murad MH, Reincke M, Shibata H, et al. The management of primary aldosteronism: case detection, diagnosis, and treatment: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2016;101(5):1889\u2013916. https:\/\/doi.org\/10.1210\/jc.2015-4061These are the most recent and comprehensive Endocrine Society guidelines for the management of primary aldosteronism.","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"1516_CR24","doi-asserted-by":"publisher","first-page":"2253","DOI":"10.1097\/hjh.0000000000001088","volume":"34","author":"P Mulatero","year":"2016","unstructured":"Mulatero P, Monticone S, Burrello J, Veglio F, Williams TA, Funder J. Guidelines for primary aldosteronism: uptake by primary care physicians in Europe. J Hypertens. 2016;34(11):2253\u20137. https:\/\/doi.org\/10.1097\/hjh.0000000000001088.","journal-title":"J Hypertens"},{"issue":"9","key":"1516_CR25","doi-asserted-by":"publisher","first-page":"3266","DOI":"10.1210\/jc.2008-0104","volume":"93","author":"JW Funder","year":"2008","unstructured":"Funder JW, Carey RM, Fardella C, Gomez-Sanchez CE, Mantero F, Stowasser M, et al. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2008;93(9):3266\u201381. https:\/\/doi.org\/10.1210\/jc.2008-0104.","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"1516_CR26","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1111\/joim.12831","volume":"285","author":"WF Young Jr","year":"2019","unstructured":"Young WF Jr. Diagnosis and treatment of primary aldosteronism: practical clinical perspectives. J Intern Med. 2019;285(2):126\u201348. https:\/\/doi.org\/10.1111\/joim.12831.","journal-title":"J Intern Med"},{"issue":"4","key":"1516_CR27","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/0002-9343(83)91022-7","volume":"74","author":"EL Bravo","year":"1983","unstructured":"Bravo EL, Tarazi RC, Dustan HP, Fouad FM, Textor SC, Gifford RW, et al. The changing clinical spectrum of primary aldosteronism. Am J Med. 1983;74(4):641\u201351. https:\/\/doi.org\/10.1016\/0002-9343(83)91022-7.","journal-title":"Am J Med"},{"issue":"7","key":"1516_CR28","doi-asserted-by":"publisher","first-page":"2618","DOI":"10.1210\/jc.2006-0078","volume":"91","author":"P Mulatero","year":"2006","unstructured":"Mulatero P, Milan A, Fallo F, Regolisti G, Pizzolo F, Fardella C, et al. Comparison of confirmatory tests for the diagnosis of primary aldosteronism. J Clin Endocrinol Metab. 2006;91(7):2618\u201323. https:\/\/doi.org\/10.1210\/jc.2006-0078.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"1516_CR29","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1161\/hypertensionaha.113.02097","volume":"63","author":"GP Rossi","year":"2014","unstructured":"Rossi GP, Auchus RJ, Brown M, Lenders JW, Naruse M, Plouin PF, et al. An expert consensus statement on use of adrenal vein sampling for the subtyping of primary aldosteronism. Hypertension. 2014;63(1):151\u201360. https:\/\/doi.org\/10.1161\/hypertensionaha.113.02097.","journal-title":"Hypertension."},{"issue":"8","key":"1516_CR30","doi-asserted-by":"publisher","first-page":"2712","DOI":"10.1210\/jc.2013-4146","volume":"99","author":"V Lim","year":"2014","unstructured":"Lim V, Guo Q, Grant CS, Thompson GB, Richards ML, Farley DR, et al. Accuracy of adrenal imaging and adrenal venous sampling in predicting surgical cure of primary aldosteronism. J Clin Endocrinol Metab. 2014;99(8):2712\u20139. https:\/\/doi.org\/10.1210\/jc.2013-4146.","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"1516_CR31","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1210\/jc.2011-2830","volume":"97","author":"GP Rossi","year":"2012","unstructured":"Rossi GP, Barisa M, Allolio B, Auchus RJ, Amar L, Cohen D, et al. The Adrenal Vein Sampling International Study (AVIS) for identifying the major subtypes of primary aldosteronism. J Clin Endocrinol Metab. 2012;97(5):1606\u201314. https:\/\/doi.org\/10.1210\/jc.2011-2830.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"1516_CR32","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1161\/hypertensionaha.118.11382","volume":"72","author":"TA Williams","year":"2018","unstructured":"Williams TA, Burrello J, Sechi LA, Fardella CE, Matrozova J, Adolf C, et al. Computed tomography and adrenal venous sampling in the diagnosis of unilateral primary aldosteronism. Hypertension. 2018;72(3):641\u20139. https:\/\/doi.org\/10.1161\/hypertensionaha.118.11382.","journal-title":"Hypertension."},{"issue":"9","key":"1516_CR33","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/s2213-8587(17)30135-3","volume":"5","author":"TA Williams","year":"2017","unstructured":"\u2022\u2022 Williams TA, Lenders JWM, Mulatero P, Burrello J, Rottenkolber M, Adolf C, et al. Outcomes after adrenalectomy for unilateral primary aldosteronism: an international consensus on outcome measures and analysis of remission rates in an international cohort. Lancet Diabetes Endocrinol. 2017;5(9):689\u201399. https:\/\/doi.org\/10.1016\/s2213-8587(17)30135-3The PASO trial describes consensus criteria for clinical and biochemical outcomes after adrenalectomy.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"4","key":"1516_CR34","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1002\/bjs.9744","volume":"102","author":"A Muth","year":"2015","unstructured":"Muth A, Ragnarsson O, Johannsson G, W\u00e4ngberg B. Systematic review of surgery and outcomes in patients with primary aldosteronism. Br J Surg. 2015;102(4):307\u201317. https:\/\/doi.org\/10.1002\/bjs.9744.","journal-title":"Br J Surg"},{"issue":"1","key":"1516_CR35","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.surg.2018.04.077","volume":"165","author":"H Wachtel","year":"2019","unstructured":"Wachtel H, Bhandari S, Roses RE, Cohen DL, Trerotola SO, Fraker DL. Primary aldosteronism with nonlocalizing imaging. Surgery. 2019;165(1):211\u20138. https:\/\/doi.org\/10.1016\/j.surg.2018.04.077.","journal-title":"Surgery."},{"issue":"7","key":"1516_CR36","doi-asserted-by":"publisher","first-page":"730","DOI":"10.5732\/cjc.009.10045","volume":"28","author":"XP Zhang","year":"2009","unstructured":"Zhang XP, Wei JX, Zhang WX, Wang ZY, Wu YD, Song DK. Transperitoneal laparoscopic adrenalectomy for adrenal neoplasm: a report of 371 cases. Ai Zheng. 2009;28(7):730\u20133. https:\/\/doi.org\/10.5732\/cjc.009.10045.","journal-title":"Ai Zheng"},{"issue":"5","key":"1516_CR37","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1007\/s00268-008-9513-0","volume":"32","author":"MK Walz","year":"2008","unstructured":"Walz MK, Gwosdz R, Levin SL, Alesina PF, Suttorp AC, Metz KA, et al. Retroperitoneoscopic adrenalectomy in Conn\u2019s syndrome caused by adrenal adenomas or nodular hyperplasia. World J Surg. 2008;32(5):847\u201353. https:\/\/doi.org\/10.1007\/s00268-008-9513-0.","journal-title":"World J Surg"},{"issue":"1","key":"1516_CR38","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1097\/01.ju.0000162045.68387.c3","volume":"174","author":"S Ishidoya","year":"2005","unstructured":"Ishidoya S, Ito A, Sakai K, Satoh M, Chiba Y, Sato F, et al. Laparoscopic partial versus total adrenalectomy for aldosterone producing adenoma. J Urol. 2005;174(1):40\u20133. https:\/\/doi.org\/10.1097\/01.ju.0000162045.68387.c3.","journal-title":"J Urol"},{"issue":"5","key":"1516_CR39","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1016\/j.juro.2010.12.051","volume":"185","author":"B Fu","year":"2011","unstructured":"Fu B, Zhang X, Wang GX, Lang B, Ma X, Li HZ, et al. Long-term results of a prospective, randomized trial comparing retroperitoneoscopic partial versus total adrenalectomy for aldosterone producing adenoma. J Urol. 2011;185(5):1578\u201382. https:\/\/doi.org\/10.1016\/j.juro.2010.12.051.","journal-title":"J Urol"},{"issue":"6","key":"1516_CR40","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1016\/s0022-5347(01)67303-8","volume":"153","author":"T Nakada","year":"1995","unstructured":"Nakada T, Kubota Y, Sasagawa I, Yagisawa T, Watanabe M, Ishigooka M. Therapeutic outcome of primary aldosteronism: adrenalectomy versus enucleation of aldosterone-producing adenoma. J Urol. 1995;153(6):1775\u201380. https:\/\/doi.org\/10.1016\/s0022-5347(01)67303-8.","journal-title":"J Urol"},{"key":"1516_CR41","doi-asserted-by":"publisher","unstructured":"Anceschi U, Tuderti G, Fiori C, Zappal\u00e0 O, Ferriero MC, Brassetti A, et al. Minimally invasive partial versus total adrenalectomy for the treatment of primary aldosteronism: results of a multicenter series according to the PASO criteria. Eur Urol Focus. 2020. https:\/\/doi.org\/10.1016\/j.euf.2020.06.023.","DOI":"10.1016\/j.euf.2020.06.023"},{"issue":"2","key":"1516_CR42","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1148\/radiol.2016152277","volume":"281","author":"SY Liu","year":"2016","unstructured":"Liu SY, Chu CC, Tsui TK, Wong SK, Kong AP, Chiu PW, et al. Aldosterone-producing adenoma in primary aldosteronism: CT-guided radiofrequency ablation-long-term results and recurrence rate. Radiology. 2016;281(2):625\u201334. https:\/\/doi.org\/10.1148\/radiol.2016152277.","journal-title":"Radiology."},{"issue":"9","key":"1516_CR43","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1016\/j.jvir.2019.04.039","volume":"30","author":"KW Liang","year":"2019","unstructured":"Liang KW, Jahangiri Y, Tsao TF, Tyan YS, Huang HH. Effectiveness of thermal ablation for aldosterone-producing adrenal adenoma: a systematic review and meta-analysis of clinical and biochemical parameters. J Vasc Interv Radiol. 2019;30(9):1335\u201342 e1. https:\/\/doi.org\/10.1016\/j.jvir.2019.04.039.","journal-title":"J Vasc Interv Radiol"},{"key":"1516_CR44","doi-asserted-by":"publisher","unstructured":"Zhang H, Li Q, Liu X, Zhao Z, He H, Sun F, et al. Adrenal artery ablation for primary aldosteronism without apparent aldosteronoma: an efficacy and safety, proof-of-principle trial. J Clin Hypertens. 2020. https:\/\/doi.org\/10.1111\/jch.13960.","DOI":"10.1111\/jch.13960"},{"issue":"7","key":"1516_CR45","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1016\/j.jvir.2016.03.042","volume":"27","author":"A Sarwar","year":"2016","unstructured":"Sarwar A, Brook OR, Vaidya A, Sacks AC, Sacks BA, Goldberg SN, et al. Clinical outcomes following percutaneous radiofrequency ablation of unilateral aldosterone-producing adenoma: comparison with adrenalectomy. J Vasc Interv Radiol. 2016;27(7):961\u20137. https:\/\/doi.org\/10.1016\/j.jvir.2016.03.042.","journal-title":"J Vasc Interv Radiol"},{"issue":"11","key":"1516_CR46","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1002\/bjs.10219","volume":"103","author":"SY Liu","year":"2016","unstructured":"Liu SY, Chu CM, Kong AP, Wong SK, Chiu PW, Chow FC, et al. Radiofrequency ablation compared with laparoscopic adrenalectomy for aldosterone-producing adenoma. Br J Surg. 2016;103(11):1476\u201386. https:\/\/doi.org\/10.1002\/bjs.10219.","journal-title":"Br J Surg"},{"key":"1516_CR47","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.pharmthera.2015.07.006","volume":"154","author":"J Deinum","year":"2015","unstructured":"Deinum J, Riksen NP, Lenders JW. Pharmacological treatment of aldosterone excess. Pharmacol Ther. 2015;154:120\u201333. https:\/\/doi.org\/10.1016\/j.pharmthera.2015.07.006.","journal-title":"Pharmacol Ther"},{"issue":"1","key":"1516_CR48","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/s2213-8587(17)30367-4","volume":"6","author":"GL Hundemer","year":"2018","unstructured":"Hundemer GL, Curhan GC, Yozamp N, Wang M, Vaidya A. Cardiometabolic outcomes and mortality in medically treated primary aldosteronism: a retrospective cohort study. Lancet Diabetes Endocrinol. 2018;6(1):51\u20139. https:\/\/doi.org\/10.1016\/s2213-8587(17)30367-4.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"3","key":"1516_CR49","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1053\/j.ackd.2014.10.003","volume":"22","author":"O Steichen","year":"2015","unstructured":"Steichen O, Lorthioir A, Zinzindohoue F, Plouin PF, Amar L. Outcomes of drug-based and surgical treatments for primary aldosteronism. Adv Chronic Kidney Dis. 2015;22(3):196\u2013203. https:\/\/doi.org\/10.1053\/j.ackd.2014.10.003.","journal-title":"Adv Chronic Kidney Dis"},{"issue":"6","key":"1516_CR50","doi-asserted-by":"publisher","first-page":"e13","DOI":"10.1161\/hyp.0000000000000065","volume":"71","author":"PK Whelton","year":"2018","unstructured":"Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Dennison Himmelfarb C, et al. 2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA Guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018;71(6):e13\u2013e115. https:\/\/doi.org\/10.1161\/hyp.0000000000000065.","journal-title":"Hypertension."},{"issue":"2","key":"1516_CR51","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1038\/sj.jhh.1001948","volume":"20","author":"JS Williams","year":"2006","unstructured":"Williams JS, Williams GH, Raji A, Jeunemaitre X, Brown NJ, Hopkins PN, et al. Prevalence of primary hyperaldosteronism in mild to moderate hypertension without hypokalaemia. J Hum Hypertens. 2006;20(2):129\u201336. https:\/\/doi.org\/10.1038\/sj.jhh.1001948.","journal-title":"J Hum Hypertens"},{"issue":"5","key":"1516_CR52","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1291\/hypres.25.737","volume":"25","author":"H Takakuwa","year":"2002","unstructured":"Takakuwa H, Shimizu K, Izumiya Y, Kato T, Nakaya I, Yokoyama H, et al. Dietary sodium restriction restores nocturnal reduction of blood pressure in patients with primary aldosteronism. Hypertens Res. 2002;25(5):737\u201342. https:\/\/doi.org\/10.1291\/hypres.25.737.","journal-title":"Hypertens Res"},{"issue":"11","key":"1516_CR53","doi-asserted-by":"publisher","first-page":"3989","DOI":"10.1210\/jc.2016-1963","volume":"101","author":"R Baudrand","year":"2016","unstructured":"Baudrand R, Guarda FJ, Torrey J, Williams G, Vaidya A. Dietary sodium restriction increases the risk of misinterpreting mild cases of primary aldosteronism. J Clin Endocrinol Metab. 2016;101(11):3989\u201396. https:\/\/doi.org\/10.1210\/jc.2016-1963.","journal-title":"J Clin Endocrinol Metab"},{"key":"1516_CR54","doi-asserted-by":"publisher","first-page":"32103","DOI":"10.1038\/srep32103","volume":"6","author":"VC Wu","year":"2016","unstructured":"\u2022 Wu VC, Wang SM, Chang CH, Hu YH, Lin LY, Lin YH, et al. Long term outcome of Aldosteronism after target treatments. Sci Rep. 2016;6:32103. https:\/\/doi.org\/10.1038\/srep32103This retrospective chort study evaluates survival outcomes in medical versus surgical managemnt of primary aldosteronism.","journal-title":"Sci Rep"},{"issue":"3","key":"1516_CR55","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1161\/HYPERTENSIONAHA.118.11568","volume":"72","author":"GL Hundemer","year":"2018","unstructured":"\u2022 Hundemer GL, Curhan GC, Yozamp N, Wang M, Vaidya A. Renal outcomes in medically and surgically treated primary aldosteronism. Hypertension. 2018;72(3):658\u201366. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.118.11568This retrospective cohort study evaluates glomerular filtration rate and incidence of chronic kidney disease in medically and surgically treated patients with primary aldosteronism compared to subjects with primary hypertension.","journal-title":"Hypertension"},{"issue":"4","key":"1516_CR56","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1161\/hypertensionaha.117.10596","volume":"71","author":"GP Rossi","year":"2018","unstructured":"\u2022 Rossi GP, Maiolino G, Flego A, Belfiore A, Bernini G, Fabris B, et al. Adrenalectomy lowers incident atrial fibrillation in primary aldosteronism patients at long term. Hypertension. 2018;71(4):585\u201391. https:\/\/doi.org\/10.1161\/hypertensionaha.117.10596This retrospective cohort study evaluates atrial fibrillation in medically and surgically treated patients with primary aldosteronism.","journal-title":"Hypertension"},{"issue":"8","key":"1516_CR57","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1001\/jamacardio.2018.03","volume":"3","author":"GL Hundemer","year":"2018","unstructured":"\u2022 Hundemer GL, Curhan GC, Yozamp N, Wang M, Vaidya A. Incidence of atrial fibrillation and mineralocorticoid receptor activity in patients with medically and surgically treated primary aldosteronism. JAMA Cardiol. 2018;3(8):768\u201374. https:\/\/doi.org\/10.1001\/jamacardio.2018.03This retrospective cohort study evaluates atrial fibrillation in medically and surgically treated patients with primary aldosteronism compared to subjects with primary hypertension. Subjects treated with mineralocorticoid antagonists to non-suppressed renin levels had equivalent therapeutic benefit to surgery.","journal-title":"JAMA Cardiol"},{"issue":"1","key":"1516_CR58","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1210\/jc.2017-01442","volume":"103","author":"M Velema","year":"2018","unstructured":"\u2022 Velema M, Dekkers T, Hermus A, Timmers H, Lenders J, Groenewoud H, et al. Quality of life in primary aldosteronism: a comparative effectiveness study of adrenalectomy and medical treatment. J Clin Endocrinol Metab. 2018;103(1):16\u201324. https:\/\/doi.org\/10.1210\/jc.2017-01442This post hoc comparative effectiveness study evaluates quality of life in subjects from the SPARTACUS trial.","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"1516_CR59","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1097\/hjh.0000000000002070","volume":"37","author":"T Katabami","year":"2019","unstructured":"\u2022 Katabami T, Fukuda H, Tsukiyama H, Tanaka Y, Takeda Y, Kurihara I, et al. Clinical and biochemical outcomes after adrenalectomy and medical treatment in patients with unilateral primary aldosteronism. J Hypertens. 2019;37(7):1513\u201320. https:\/\/doi.org\/10.1097\/hjh.0000000000002070This retrospective cohort study compares outcomes in primary aldosteronism patients treated with medical and surgical management.","journal-title":"J Hypertens"},{"issue":"2","key":"1516_CR60","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.surg.2019.08.017","volume":"167","author":"YH Chang","year":"2020","unstructured":"\u2022 Chang YH, Chung SD, Wu CH, Chueh JS, Chen L, Lin PC, et al. Surgery decreases the long-term incident stroke risk in patients with primary aldosteronism. Surgery. 2020;167(2):367\u201377. https:\/\/doi.org\/10.1016\/j.surg.2019.08.017This retrospective cohort study investigates the risk of stroke in patients with primary aldosteronism treated with adrenalectomy or mineralocorticoid antagonists compared to matched controls with primary hypertension.","journal-title":"Surgery"},{"issue":"5","key":"1516_CR61","doi-asserted-by":"publisher","first-page":"e013699","DOI":"10.1161\/jaha.119.013699","volume":"9","author":"CT Pan","year":"2020","unstructured":"\u2022 Pan CT, Liao CW, Tsai CH, Chen ZW, Chen L, Hung CS, et al. Influence of different treatment strategies on new-onset atrial fibrillation among patients with primary aldosteronism: a nationwide longitudinal cohort-based study. J Am Heart Assoc. 2020;9(5):e013699. https:\/\/doi.org\/10.1161\/jaha.119.013699This retrospective cohort study evaluates rates of new onset atrial fibrillation in primary aldosterone patient treated medically and surgically compared to matched controls with primary hypertension.","journal-title":"J Am Heart Assoc"},{"issue":"14","key":"1516_CR62","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1016\/j.jacc.2017.01.052","volume":"69","author":"S Monticone","year":"2017","unstructured":"Monticone S, Burrello J, Tizzani D, Bertello C, Viola A, Buffolo F, et al. Prevalence and clinical manifestations of primary aldosteronism encountered in primary care practice. J Am Coll Cardiol. 2017;69(14):1811\u201320. https:\/\/doi.org\/10.1016\/j.jacc.2017.01.052.","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"1516_CR63","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1097\/hjh.0000000000001251","volume":"35","author":"M Murata","year":"2017","unstructured":"Murata M, Kitamura T, Tamada D, Mukai K, Kurebayashi S, Yamamoto T, et al. Plasma aldosterone level within the normal range is less associated with cardiovascular and cerebrovascular risk in primary aldosteronism. J Hypertens. 2017;35(5):1079\u201385. https:\/\/doi.org\/10.1097\/hjh.0000000000001251.","journal-title":"J Hypertens"},{"issue":"1","key":"1516_CR64","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1001\/archinternmed.2007.33","volume":"168","author":"C Catena","year":"2008","unstructured":"Catena C, Colussi G, Nadalini E, Chiuch A, Baroselli S, Lapenna R, et al. Cardiovascular outcomes in patients with primary aldosteronism after treatment. Arch Intern Med. 2008;168(1):80\u20135. https:\/\/doi.org\/10.1001\/archinternmed.2007.33.","journal-title":"Arch Intern Med"},{"issue":"12","key":"1516_CR65","doi-asserted-by":"publisher","first-page":"4826","DOI":"10.1210\/jc.2013-2805","volume":"98","author":"P Mulatero","year":"2013","unstructured":"Mulatero P, Monticone S, Bertello C, Viola A, Tizzani D, Iannaccone A, et al. Long-term cardio- and cerebrovascular events in patients with primary aldosteronism. J Clin Endocrinol Metab. 2013;98(12):4826\u201333. https:\/\/doi.org\/10.1210\/jc.2013-2805.","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"1516_CR66","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1007\/bf03347840","volume":"18","author":"R Takeda","year":"1995","unstructured":"Takeda R, Matsubara T, Miyamori I, Hatakeyama H, Morise T. Vascular complications in patients with aldosterone producing adenoma in Japan: comparative study with essential hypertension. The Research Committee of Disorders of Adrenal Hormones in Japan. J Endocrinol Investig. 1995;18(5):370\u20133. https:\/\/doi.org\/10.1007\/bf03347840.","journal-title":"J Endocrinol Investig"},{"issue":"3","key":"1516_CR67","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1161\/hypertensionaha.112.197111","volume":"60","author":"M Reincke","year":"2012","unstructured":"Reincke M, Fischer E, Gerum S, Merkle K, Schulz S, Pallauf A, et al. Observational study mortality in treated primary aldosteronism: the German Conn\u2019s registry. Hypertension. 2012;60(3):618\u201324. https:\/\/doi.org\/10.1161\/hypertensionaha.112.197111.","journal-title":"Hypertension."},{"issue":"1","key":"1516_CR68","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/s2213-8587(17)30319-4","volume":"6","author":"S Monticone","year":"2018","unstructured":"\u2022\u2022 Monticone S, D'Ascenzo F, Moretti C, Williams TA, Veglio F, Gaita F, et al. Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2018;6(1):41\u201350. https:\/\/doi.org\/10.1016\/s2213-8587(17)30319-4This meta-analysis summarizes the cardiovascular complications and end organ injury associated with primary aldosteronism.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"6","key":"1516_CR69","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1210\/er.2018-00139","volume":"39","author":"A Vaidya","year":"2018","unstructured":"Vaidya A, Mulatero P, Baudrand R, Adler GK. The expanding spectrum of primary aldosteronism: implications for diagnosis, pathogenesis, and treatment. Endocr Rev. 2018;39(6):1057\u201388. https:\/\/doi.org\/10.1210\/er.2018-00139.","journal-title":"Endocr Rev"},{"issue":"22","key":"1516_CR70","doi-asserted-by":"publisher","first-page":"2638","DOI":"10.1001\/jama.295.22.2638","volume":"295","author":"LA Sechi","year":"2006","unstructured":"Sechi LA, Novello M, Lapenna R, Baroselli S, Nadalini E, Colussi GL, et al. Long-term renal outcomes in patients with primary aldosteronism. JAMA. 2006;295(22):2638\u201345. https:\/\/doi.org\/10.1001\/jama.295.22.2638.","journal-title":"JAMA"},{"issue":"3","key":"1516_CR71","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1210\/jc.2008-1851","volume":"94","author":"M Reincke","year":"2009","unstructured":"Reincke M, Rump LC, Quinkler M, Hahner S, Diederich S, Lorenz R, et al. Risk factors associated with a low glomerular filtration rate in primary aldosteronism. J Clin Endocrinol Metab. 2009;94(3):869\u201375. https:\/\/doi.org\/10.1210\/jc.2008-1851.","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"1516_CR72","doi-asserted-by":"publisher","first-page":"2904","DOI":"10.1210\/jc.2011-0138","volume":"96","author":"AH Ahmed","year":"2011","unstructured":"Ahmed AH, Gordon RD, Sukor N, Pimenta E, Stowasser M. Quality of life in patients with bilateral primary aldosteronism before and during treatment with spironolactone and\/or amiloride, including a comparison with our previously published results in those with unilateral disease treated surgically. J Clin Endocrinol Metab. 2011;96(9):2904\u201311. https:\/\/doi.org\/10.1210\/jc.2011-0138.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"1516_CR73","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1210\/jc.2009-1763","volume":"95","author":"N Sukor","year":"2010","unstructured":"Sukor N, Kogovsek C, Gordon RD, Robson D, Stowasser M. Improved quality of life, blood pressure, and biochemical status following laparoscopic adrenalectomy for unilateral primary aldosteronism. J Clin Endocrinol Metab. 2010;95(3):1360\u20134. https:\/\/doi.org\/10.1210\/jc.2009-1763.","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"1516_CR74","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1055\/s-0043-121706","volume":"49","author":"MS Velema","year":"2017","unstructured":"Velema MS, de Nooijer AH, Burgers VWG, Hermus A, Timmers H, Lenders JWM, et al. Health-related quality of life and mental health in primary aldosteronism: a systematic review. Horm Metab Res. 2017;49(12):943\u201350. https:\/\/doi.org\/10.1055\/s-0043-121706.","journal-title":"Horm Metab Res"},{"issue":"4","key":"1516_CR75","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1530\/ec-19-0026","volume":"8","author":"MS Velema","year":"2019","unstructured":"Velema MS, de Nooijer A, Hermus A, Timmers H, Lenders JWM, Husson O, et al. A disease-specific quality of Life questionnaire for primary aldosteronism. Endocr Connect. 2019;8(4):389\u201397. https:\/\/doi.org\/10.1530\/ec-19-0026.","journal-title":"Endocr Connect"},{"issue":"10","key":"1516_CR76","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1001\/jamasurg.2016.2310","volume":"151","author":"SM Wilhelm","year":"2016","unstructured":"Wilhelm SM, Wang TS, Ruan DT, Lee JA, Asa SL, Duh QY, et al. The American Association of Endocrine Surgeons Guidelines for Definitive Management of Primary Hyperparathyroidism. JAMA Surg. 2016;151(10):959\u201368. https:\/\/doi.org\/10.1001\/jamasurg.2016.2310.","journal-title":"JAMA Surg"}],"container-title":["Current Cardiology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-021-01516-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11886-021-01516-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-021-01516-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,7]],"date-time":"2021-07-07T06:58:19Z","timestamp":1625641099000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11886-021-01516-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,3]]},"references-count":76,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["1516"],"URL":"https:\/\/doi.org\/10.1007\/s11886-021-01516-0","relation":{},"ISSN":["1523-3782","1534-3170"],"issn-type":[{"value":"1523-3782","type":"print"},{"value":"1534-3170","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,3]]},"assertion":[{"value":"15 April 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Heather Wachtel and Douglas L. Fraker declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"89"}}